Proprietary AI analyst is now available
- Public Comps
- Abeona Therapeutics
Abeona Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Abeona Therapeutics and similar public comparables like Racura Oncology, Cybin, Luzhu Biotech, Medy-Tox and more.
Abeona Therapeutics Overview
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Founded
1974
HQ

Employees
136
Website
Financials (LTM)
EV
$183M
Valuation Multiples
Start free trialAbeona Therapeutics Financials
Abeona Therapeutics reported last 12-month revenue of $35M.
In the same LTM period, Abeona Therapeutics generated $26M in gross profit and $17M in net income.
Revenue (LTM)
Abeona Therapeutics P&L
In the most recent fiscal year, Abeona Therapeutics reported revenue of $6M and EBITDA of $79M.
Abeona Therapeutics is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.
Financial data powered by Morningstar, Inc.
Abeona Therapeutics Stock Performance
Abeona Therapeutics has current market cap of $328M, and enterprise value of $183M.
Market Cap Evolution
Abeona Therapeutics' stock price is $5.75.
Abeona Therapeutics share price decreased by 0.9% in the last 30 days, and increased by 1.2% in the last year.
Abeona Therapeutics has an EPS (earnings per share) of $1.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $183M | $328M | -0.3% | -0.9% | 28.3% | 1.2% | $1.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbeona Therapeutics Valuation Multiples
Abeona Therapeutics trades at 5.3x EV/Revenue multiple, and 2.3x EV/EBITDA.
EV / Revenue (LTM)
Abeona Therapeutics Financial Valuation Multiples
As of June 23, 2026, Abeona Therapeutics has market cap of $328M and EV of $183M.
Abeona Therapeutics has a P/E ratio of 19.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abeona Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Abeona Therapeutics Margins & Growth Rates
Abeona Therapeutics grew revenue by 1039% but net profit decreased by 159% in the last fiscal year.
In the most recent fiscal year, Abeona Therapeutics reported gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.
Abeona Therapeutics Margins
Abeona Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Operational KPIs
Abeona Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Competitors
Abeona Therapeutics competitors include Racura Oncology, Cybin, Luzhu Biotech, Medy-Tox, Dong-A Socio Holdings, Amarin Corp, OmniAb, Opus Genetics, Palisade Bio and Biofarm.
Most Abeona Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | 92.4x | - | (91.6x) | |||
| - | - | - | - | |||
| - | 6.7x | (14.4x) | 158.2x | |||
| 2.3x | 2.3x | 18.8x | 14.7x | |||
| 0.7x | 0.6x | 5.5x | 5.8x | |||
| 0.1x | 0.2x | (0.9x) | (0.8x) | |||
| 16.4x | 12.5x | (6.8x) | (7.7x) | |||
| 19.5x | 18.8x | (5.8x) | - | |||
This data is available for Pro users. Sign up to see all Abeona Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abeona Therapeutics
| When was Abeona Therapeutics founded? | Abeona Therapeutics was founded in 1974. |
| Where is Abeona Therapeutics headquartered? | Abeona Therapeutics is headquartered in United States. |
| How many employees does Abeona Therapeutics have? | As of today, Abeona Therapeutics has over 136 employees. |
| Who is the CEO of Abeona Therapeutics? | Abeona Therapeutics' CEO is Vishwas Seshadri. |
| Is Abeona Therapeutics publicly listed? | Yes, Abeona Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Abeona Therapeutics? | Abeona Therapeutics trades under ABEO ticker. |
| When did Abeona Therapeutics go public? | Abeona Therapeutics went public in 1980. |
| Who are competitors of Abeona Therapeutics? | Abeona Therapeutics main competitors include Racura Oncology, Cybin, Luzhu Biotech, Medy-Tox, Dong-A Socio Holdings, Amarin Corp, OmniAb, Opus Genetics, Palisade Bio, Biofarm. |
| What is the current market cap of Abeona Therapeutics? | Abeona Therapeutics' current market cap is $328M. |
| What is the current revenue of Abeona Therapeutics? | Abeona Therapeutics' last 12 months revenue is $35M. |
| What is the current revenue growth of Abeona Therapeutics? | Abeona Therapeutics revenue growth (NTM/LTM) is 192%. |
| What is the current EV/Revenue multiple of Abeona Therapeutics? | Current revenue multiple of Abeona Therapeutics is 5.3x. |
| What is the current net income of Abeona Therapeutics? | Abeona Therapeutics' last 12 months net income is $17M. |
| How many companies Abeona Therapeutics has acquired to date? | Abeona Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Abeona Therapeutics has invested to date? | Abeona Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Abeona Therapeutics
Lists including Abeona Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.